

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (Not for submission under 37 CFR 1.99)	Application Number		10582304	
	Filing Date		2007-04-20	
	First Named Inventor	Kimura et al.		
	Art Unit	1643		
	Examiner Name	Anne Gussow		
	Attorney Docket Number	14875-0166US1		

U.S. PATENTS						Remove
Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1	7115373	B2	2009-10-27	HASHIDA et al.	

If you wish to add additional U.S. Patent citation information please click the Add button.

Add

U.S. PATENT APPLICATION PUBLICATIONS						Remove
Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1	20090297501	A1	2009-12-03	IGAWA et al.	
	2	20030103979	A1	2003-06-05	LEUNG et al.	

If you wish to add additional U.S. Published Application citation information please click the Add button.

Add

FOREIGN PATENT DOCUMENTS							Remove	
Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup> ;	Kind Code <sup>4</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T <sup>5</sup>
	1	WO97034632	WO		1997-09-25	LEUNG et al.		<input type="checkbox"/>
	2	WO03002607	WO	A1	2003-01-09	LEUNG et al.		<input type="checkbox"/>

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	10582304
Filing Date	2007-04-20
First Named Inventor	Kimura et al.
Art Unit	1643
Examiner Name	Anne Gussow
Attorney Docket Number	14875-0166US1

3	JP10508868	JP		1998-09-02	UCKUN et al.		<input type="checkbox"/>
4	JP2005529616	JP		2005-10-06	DEVERAUX et al.		<input type="checkbox"/>
5	WO02028894	WO		2002-04-11	KOMATANI et al.		<input type="checkbox"/>
6	WO2005004912	WO		2005-01-20	NAKAMURA et al.		<input type="checkbox"/>
7	WO2008007755	WO		2008-01-17	KIMURA et al.		<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button

**NON-PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T5
	1	SACKSTEIN, "The lymphocyte homing receptors: gatekeepers of the multistep paradigm," Current Opinion in Hematology, 12:444-450 (2005)	<input type="checkbox"/>
	2	U.S. EXAMINER PENSEE T. DO, USPTO Restriction Requirement in U.S. App. Ser. No. 10/582,176, mailed October 19, 2009, 6 pages	<input type="checkbox"/>
	3	U.S. EXAMINER BRADLEY DUFFY, USPTO Interview Summary in U.S. App. Ser. No. 10/582,413, mailed October 27, 2009, 4 pages	<input type="checkbox"/>
	4	FISH & RICHARDSON P.C., Response to Restriction Requirement dated October 19, 2009 in U.S. App. Ser. No. 10/582,176, filed November 4, 2009, 1 page	<input type="checkbox"/>

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	10582304
Filing Date	2007-04-20
First Named Inventor	Kimura et al.
Art Unit	1643
Examiner Name	Anne Gussow
Attorney Docket Number	14875-0166US1

5	BORDEN et al., "Lymphokines and Cytokines as Cancer Treatment," Cancer, 65:800-814 (1990)	<input type="checkbox"/>
6	BYERS, "What Can Randomized Controlled Trials Tell us About Nutrition and Cancer Prevention?," CA Cancer J. Clin., 49:353-361 (1999)	<input type="checkbox"/>
7	GRANZIERO et al., "Adoptive immunotherapy prevents prostate cancer in a transgenic animal model," Eur. J. Immunol., 29:1127-1138 (1999)	<input type="checkbox"/>
8	U.S. EXAMINER ELLY GERALD STOICA, USPTO Non-Final Office Action in U.S. App. Ser. No. 11/913,229, mailed November 3, 2009, 40 pages	<input type="checkbox"/>
9	U.S. EXAMINER SHULAMITH H. SHAFER, USPTO Notice of Allowance in U.S. App. Ser. No. 10/548,727, mailed November 25, 2009, 29 pages	<input type="checkbox"/>
10	FISH & RICHARDSON, Amendment in Reply to Action dated June 8, 2009 in U.S. App. Ser. No. 10/530,696, filed November 30, 2009, 10 pages	<input type="checkbox"/>
11	FISH & RICHARDSON P.C., Amendment in Reply to Action dated June 1, 2009 in U.S. App. Ser. No. 11/547,747, filed November 30, 2009, 12 pages	<input type="checkbox"/>
12	U.S. EXAMINER BRADLEY DUFFY, USPTO Interview Summary in U.S. App. Ser. No. 10/582,413, mailed December 2, 2009, 4 pages	<input type="checkbox"/>
13	U.S. EXAMINER ANNE GUSSOW, USPTO Non-Final Office Action in U.S. App. Ser. No. 10/550,934, mailed December 8, 2009, 33 pages	<input type="checkbox"/>
14	FISK et al., "Increased sensitivity of Adriamycin-selected Tumor Lines to CTL-mediated Lysis Results in Enhanced Drug Sensitivity," Cancer Res., 58:4790-4793 (1998)	<input type="checkbox"/>
15	JALILI et al., "Multi-Drug Resistant Leukemic Cells Highly Express HLA Class I Molecules and Single-Chain Fv Diabody Specific to HLA-A Overcomes Drug Resistance in These Cells," Blood (ASH Annual Meeting Abstracts), 118 (11):701a-702a (#2376) (2007)	<input type="checkbox"/>

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	10582304
Filing Date	2007-04-20
First Named Inventor	Kimura et al.
Art Unit	1643
Examiner Name	Anne Gussow
Attorney Docket Number	14875-0166US1

16	MELGUIZO et al., "Modulation of HLA class I expression in multidrug-resistant human rhabdomyosarcoma cells," Neoplasms, 50(2):91-96 (2003)	<input type="checkbox"/>
17	OZAKI et al., "Induction of myeloma cell death by a recombinant HLA class I-specific single-chain Fv diabody," Dai 65 Nihon Ketsueki Gakkai, Dai 45 kai Nihon Ketsueki Gakkai Sokai, Osaka (August 28-31, 2003)	<input checked="" type="checkbox"/>
18	OZAKI et al., "A recombinant HLA class I-specific single chain Fv diabody induces cell death in human lymphoid malignancies," 45th Annual Meeting of the American Society of Hematology, San Diego, CA, USA (December 6-9, 2003)	<input type="checkbox"/>
19	PRADOS et al., "Induction of drug resistance in embryonal rhabdomyosarcoma treated with conventional chemotherapy is associated with HLA class I increase," Neoplasms, 53(3):226-231 (2006)	<input type="checkbox"/>
20	SEKIMOTO et al., "Eradication of human myeloma cells by a recombinant HLA class I-specific single chain Fv diabody," 45th Annual Meeting of the American Society of Hematology, San Diego, CA, USA (December 6-9, 2003)	<input type="checkbox"/>
21	SONNEVELD, "Multidrug resistance in haematological malignancies," J. Intern. Med., 247:521-534 (2000)	<input type="checkbox"/>
22	TSUKAKOSHI, New Pharmacology, 3rd revised edition, Nankodo Co., Ltd., 557-568 (1997)	<input type="checkbox"/>
23	JAPANESE PATENT OFFICE, International Search Report for App. Ser. No. PCT/JP2008/054443, dated May 27, 2008, 7 pages	<input type="checkbox"/>
24	U.S. EXAMINER SHULAMITH H. SHAFER, USPTO Notice of Allowance in U.S. App. Ser. No. 10/551,504, mailed January 7, 2010, 46 pages	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

**EXAMINER SIGNATURE**

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	10582304
Filing Date	2007-04-20
First Named Inventor	Kimura et al.
Art Unit	1643
Examiner Name	Anne Gussow
Attorney Docket Number	14875-0166US1

<sup>1</sup> See Kind Codes of USPTO Patent Documents at [www.USPTO.GOV](http://www.USPTO.GOV) or MPEP 901.04. <sup>2</sup> Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>3</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>4</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>5</sup> Applicant is to place a check mark here if English language translation is attached.